Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Ron Dior who wrote (1058)	5/20/1998 12:32:00 PM
From: ACC	Read Replies (1) \| Respond to of 2135

As the long-term followers of this thread have repeatedly noted, the science behind EntreMed is solid and the clinical implications are astounding, BUT still relatively far from entering trials. Before all the hooplah began the main concern was whether ENMD can produce angio/endostatins in sufficient quantities for patient use, to see just how similar men are to mice. This has all been noted by Dr. Folkman as well as the folks at ENMD. Prior to May 4, ENMD had been a "buy, hold and wait." All the hype and spam have been generated from the excessive media attention... good luck to anyone that picked up ENMD reflexively after May 4. ACC